

## ASX RELEASE

### **Volpara grows patent collection with recently granted European protection of image quantification**

#### **Highlights:**

- **The latest European patent to be granted to Volpara highlights improved analysis of several quantitative measures from low-dose images, enabling highly accurate assessment of a woman's breast composition at an early age, and calculation of her baseline risk of breast cancer**

Wellington, NZ, 15 July 2021: Volpara Health Technologies ("Volpara," "the Group," or "the Company"; ASX: VHT), a health technology software company whose integrated breast care platform assists in the delivery of personalised breast care, has recently been granted another patent by the European Patent Office, raising the total number of patents to 98. This latest patent, effective across 25 European countries, outlines the Volpara method of image quantification, used in multiple instances across the Volpara Breast Health Platform product suite.

This latest patent highlights improved analysis of several quantitative measures from low-dose images, enabling highly accurate assessment of a woman's breast composition at an early age, and calculation of her baseline risk of breast cancer. In addition to improving outcomes for women, the improvements will help optimise clinical workflow.

Research studies are beginning to suggest patients receive a baseline mammogram to assess their breast density and breast cancer risk before they reach the screening age of 40. A patient who receives a high breast cancer risk score may be directed to begin annual screenings earlier than usual.

One of the concerns with offering women between the ages of 25 and 30 a baseline screening exam has been the effect of the exam's radiation. High-sensitivity, low-dose imaging has the potential to offer patients a way around this issue—a solution in line with Volpara's aim to achieve personalised breast cancer screening for all women.

"Securing our 98th patent is another major step forward for the company, reaffirming our position as a leading innovator in the medical imaging space, and a testament to our R&D

team who are constantly pushing the boundaries in novel and important directions, ever seeking to improve the early detection of cancer," said Volpara CEO Ralph Highnam.

This patent, together with the entire Volpara patent portfolio, serves to protect all the company's products. In sum, these patents are effective across 27 countries, including most of Europe, the United States, and China.

"These patents work together with Volpara's other international intellectual property rights to facilitate the sales and growth strategy for Volpara's product line, including software geared toward patient reporting and communication, image/exam quality monitoring and feedback, and automated breast density calculations, as well as a full risk program," said Volpara CFO Craig Hadfield.

Early cancer detection is key to fulfilling the Volpara mission to eliminate advanced-stage breast cancer and save families from cancer.

#### **Authorisation & Additional Information**

This announcement was authorised by the CEO of Volpara Health Technologies Limited.

#### **ENDS**

#### **For further information, please contact:**

Ralph Highnam, CEO  
Volpara Health Technologies  
[ralph.highnam@volparahealth.com](mailto:ralph.highnam@volparahealth.com)  
t: +64 21 149 0541

Trevor Chappell  
WE Communications  
[WE-AUVolpara@we-worldwide.com](mailto:WE-AUVolpara@we-worldwide.com)  
t: +61 407 933 437

#### **About Volpara Health Technologies Limited (ASX: VHT)**

VHT is a health technology software company founded in 2009 on research originally conducted at Oxford University. VHT's clinical functions for screening clinics provide feedback on breast density, compression, dose, and quality, while its enterprise-wide practice-management software helps with productivity, compliance, reimbursement, and patient tracking.

VHT's technology and services have been used by customers and/or research projects in 39 countries and are supported by numerous patents, trademarks, and regulatory clearances,

including FDA clearance and CE marking. Since its listing on the ASX in April 2016, VHT has raised A\$132 million, including A\$37 million in April/May 2020, and has made two significant acquisitions in MRS Systems, Inc. (patient tracking software), and CRA Health, LLC (risk and genetics software). VHT is based in Wellington, New Zealand.

For more information, visit [www.volparahealth.com](http://www.volparahealth.com)